We are international
Donate
• meetings TEXT SIZE   


Key Myeloma Questions 2010: Latest Developments in Diagnosis, Prognosis and Treatment
Fri, Dec 03, 2010


CME-CERTIFIED SATELLITE SYMPOSIUM
Key Myeloma Questions 2010: Latest Developments in Diagnosis, Prognosis and Treatment
Friday, December 3, 2010, in Orlando, Florida



Register Today for This Satellite Symposium
Jointly sponsored by Postgraduate Institute for Medicine, the International Myeloma Foundation, and Clinical Care Options, LLC


Register today for this CME-certified Friday satellite symposium on multiple myeloma preceding the 52nd ASH Annual Meeting.
In this interactive case-based didactic program, expert faculty members discuss evolving data in the optimal management of patients with multiple myeloma—from diagnosis to treatment. Audience participation includes both polling questions and question and answer sessions after each presentation.


DATE, TIME, AND LOCATION


Friday, December 3, 2009

6:00 PM - 9:00 PM

Registration and Dinner

6:00 PM - 6:30 PM

Symposium

6:30 PM - 9:00 PM

Peabody Orlando Hotel
Plaza International Ballroom H
9801 International Drive
Orlando, Florida


AGENDA

Welcome and Introduction
Program Director: Brian G. M. Durie, MD

Case Study 1: Diagnosis, Prognosis, and Risk Assessment in Multiple Myeloma
S. Vincent Rajkumar, MD

Case Study 2: Evolving Treatment Approaches in Transplantation-Eligible Patients
Jesús F. San-Miguel MD, PhD

Case Study 3: Emerging Therapies for Transplantation-Ineligible Patients
Antonio Palumbo, MD

Case Study 4: Consolidation and Maintenance Therapy in Myeloma
Philippe Moreau, MD

Case Study 5: Novel Agents and Regimens
Robert Z. Orlowski, MD, PhD

Conclusion: Faculty Panel Commentary, Recommendations, Audience Questions, and Concluding Remarks
Brian G. M. Durie, MD

Register for this satellite symposium online at:
http://clinicaloptions.com/Oncology/Live%20Events/Satellite%20Symposium/Multiple%20Myeloma%202010.aspx



 

Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower, the International Myeloma Foundation, and Clinical Care Options, LLC.

Supported by educational grants from Celgene, Lilly USA, LLC, Merck Oncology, Millennium Pharmaceuticals, Inc., and Onyx Pharmaceuticals, In
c.